Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Autologous CD19 CAR-T”

119 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 119 results

Testing effectiveness (Phase 2)UnknownNCT02963038
What this trial is testing

CAR T Cells for Refractory B Cell Malignancy

Who this might be right for
B-Cell LeukemiaB-Cell Lymphoma
Hebei Senlang Biotechnology Inc., Ltd. 10
Not applicableLooking for participantsNCT06503224
What this trial is testing

An Exploratory Clinical Study of SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases

Who this might be right for
Autoimmune Diseases
The First Affiliated Hospital of University of Science and Technology of China 18
Early research (Phase 1)Looking for participantsNCT07403097
What this trial is testing

Study of CD19 CAR-T Therapy for Refractory SLE

Who this might be right for
Systemic Lupus Erythematosus
Chongqing Precision Biotech Co., Ltd 18
Early research (Phase 1)UnknownNCT05640713
What this trial is testing

Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy

Who this might be right for
Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited
Henan Cancer Hospital 12
Early research (Phase 1)Enrolling By InvitationNCT07038447
What this trial is testing

KITE-363 in Participants With Refractory Autoimmune Diseases

Who this might be right for
Systemic Lupus ErythematosusLupus NephritisSystemic Sclerosis+1 more
Kite, A Gilead Company 52
Large-scale testing (Phase 3)Ended earlyNCT05664217
What this trial is testing

NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

Who this might be right for
Non-Hodgkin LymphomaRelapsed/Refractory Diffuse Large B-cell Lymphoma
Nektar Therapeutics 15
Early research (Phase 1)Looking for participantsNCT07331467
What this trial is testing

Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE

Who this might be right for
Systemic Lupus Erythematosus
Chongqing Precision Biotech Co., Ltd 18
Early research (Phase 1)Looking for participantsNCT07361094
What this trial is testing

Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

Who this might be right for
Relapsed/Refractory Systemic Lupus ErythematosusRelapsed/Refractory Systemic SclerosisRelapsed/Refractory Idiopathic Inflammatory Myopathies+3 more
Beijing Boren Hospital 12
Testing effectiveness (Phase 2)Study completedNCT07236151
What this trial is testing

Sequential CD19/CD22 CAR-T Cell Therapy Following ASCT

Who this might be right for
Large B-cell LymphomaCAR T Cell TherapyAuto Stem Cell Transplant
The First Affiliated Hospital of Soochow University 23
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07006805
What this trial is testing

RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis

Who this might be right for
Relapsing Multiple Sclerosis (RMS)Progressive Multiple Sclerosis (PMS)Multiple Sclerosis - Relapsing Remitting+4 more
Cabaletta Bio 12
Testing effectiveness (Phase 2)Looking for participantsNCT05480449
What this trial is testing

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

Who this might be right for
B Cell Acute Lymphoblastic Leukemia (B-ALL)B Lineage Lymphoblastic Lymphoma
Stephan Grupp MD PhD 89
Early research (Phase 1)Looking for participantsNCT06408194
What this trial is testing

Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

Who this might be right for
LeukemiaAcute Lymphoblastic Leukemia
Stanford University 20
Testing effectiveness (Phase 2)Looking for participantsNCT05470777
What this trial is testing

CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
The First Affiliated Hospital of Soochow University 37
Large-scale testing (Phase 3)Not Yet RecruitingNCT07391657
What this trial is testing

A Phase III, Open-label, Randomised, Multicentre Study to Evaluate AZD0120 in Participants With Relapsed Refractory Multiple Myeloma.

Who this might be right for
Relapsed Refractory Multiple Myeloma
AstraZeneca 508
Early research (Phase 1)Looking for participantsNCT05801913
What this trial is testing

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma

Who this might be right for
High Grade B-Cell Non-Hodgkin's LymphomaIntermediate Grade B-Cell Non-Hodgkin's LymphomaRecurrent B-Cell Non-Hodgkin Lymphoma+1 more
City of Hope Medical Center 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT05938725
What this trial is testing

KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Who this might be right for
Lupus NephritisLupus Nephritis - World Health Organization (WHO) Class IIILupus Nephritis - WHO Class IV
Kyverna Therapeutics 6
Early research (Phase 1)Active Not RecruitingNCT04049513
What this trial is testing

ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)

Who this might be right for
Lymphomas Non-Hodgkin's B-CellDiffuse Large B-cell Lymphoma (DLBCL)Primary Mediastinal B-cell Lymphoma (PMBCL)+3 more
Malaghan Institute of Medical Research 30
Testing effectiveness (Phase 2)Study completedNCT03994913
What this trial is testing

Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma

Who this might be right for
Refractory B-Cell Non-Hodgkin LymphomaRelapsed B-cell Non-Hodgkin Lymphoma
CARsgen Therapeutics Co., Ltd. 20
Testing effectiveness (Phase 2)Looking for participantsNCT06698484
What this trial is testing

To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)

Who this might be right for
Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma
National University of Malaysia 20
Testing effectiveness (Phase 2)Looking for participantsNCT05421663
What this trial is testing

JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

Who this might be right for
Lymphoma, Non-HodgkinLymphoma, B-CellLymphoma, Large B-Cell, Diffuse
Janssen Research & Development, LLC 439
Load More Results